Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408547 | 0.89 | LTA4H (0.62) | KMT2AGLALTA4HSMN1; SMN2CYP4F2 | |
| SCHEMBL7111468 | 0.88 | SMN1; SMN2 (0.59) | KMT2AGLALTA4HSMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL4929800 | 0.87 | LTA4H (0.60) | KMT2AGLALTA4HSMN1; SMN2CYP4F2 | |
| SCHEMBL9832496 | 0.87 | KDM4E (0.58) | KMT2AGLALTA4HSMN1; SMN2MEN1 | |
| SCHEMBL490909 | 0.85 | CYP4F2 (0.70) | KMT2AGLAF2RL1CYP4F2CYP4A11 | |
| SCHEMBL3548117 | 0.84 | LTA4H (0.62) | LTA4HSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL3196104 | 0.82 | MEN1 (0.62) | KMT2ASMN1; SMN2MEN1ATMF2RL1 | |
| SCHEMBL1239542 | 0.82 | ALOX5 (0.65) | KMT2AGLAF2RL1CYP4F2CYP4A11 | |
| SCHEMBL5176477 | 0.82 | LTA4H (0.74) | KMT2ALTA4HMEN1 | |
| SCHEMBL16839911 | 0.82 | LTA4H (0.57) | LTA4HCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1154992-A4 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN INC (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1154992-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050390-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | KMT2A 1817/4885GLA 221/4885LTA4H 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.